Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTD vs VATD in Relapsed/Refractory Multiple Myeloma
NCT00111748Phase 3Completed
- Sponsor
- University of Arkansas
- Start
- Feb 2005
- Primary completion
- Sep 2006
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegylated liposomal doxorubicin in multiple myeloma (MM) (2 arms), sponsored by University of Arkansas. Primary endpoint: Effectiveness of the combination at 168 days. Started Feb 2005; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00111748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111748.